Clinical Predictors and Risk Factors for Relapsing Clostridium difficile Infection

被引:41
|
作者
Cadena, Jose [1 ,4 ]
Thompson, George R., III [1 ,4 ]
Patterson, Jan E. [1 ,4 ]
Nakashima, Brandy [1 ,3 ]
Owens, Aaron [4 ,6 ]
Echevarria, Kelly [1 ,2 ,7 ]
Mortensen, Eric M. [1 ,3 ,5 ]
机构
[1] S Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX 78229 USA
[2] S Texas Vet Hlth Care Syst, Dept Pharm, San Antonio, TX 78229 USA
[3] S Texas Vet Hlth Care Syst, VERDICT Res Unit, San Antonio, TX 78229 USA
[4] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA
[5] Univ Texas Hlth Sci Ctr San Antonio, Div Gen Internal Med, San Antonio, TX 78229 USA
[6] Univ Texas Hlth Sci Ctr San Antonio, Hosp Med, San Antonio, TX 78229 USA
[7] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Resource Ctr, San Antonio, TX 78229 USA
关键词
Relapse; Clostridium difficile; Antibiotic-associated diarrhea; CDI; Mortality; PROTON-PUMP INHIBITORS; FLUOROQUINOLONE USE; DIARRHEA; DISEASE; EPIDEMIC; COLITIS; QUEBEC; ASSOCIATION; STRAIN; VALIDATION;
D O I
10.1097/MAJ.0b013e3181d3cdaa
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Clostridium difficile infection (CDI) is a common cause of morbidity among hospitalized patients. Multiple factors have been associated with primary CDI, but risk factors for CDI relapses are less well described. Methods: This was a retrospective cohort study of patients with CDI over a 15-month period. We compared patients with relapsing and nonrelapsing CDI, including risk factors associated with primary CDI and other variables hypothesized to be associated with relapsing CDI and 90-day mortality. Multivariable logistic regression models were created to examine risk factors for relapse and 90-day mortality. Results: One hundred twenty-nine consecutive patients with CDI were included; 38 (29%) had relapsing CDI. Factors associated with relapsing CDI included fluoroquinolone use (71% versus 49%, P = 0.04) and incidence of stroke (29% versus 12%, P = 0.02). In a regression model, use of a fluoroquinolone was associated with relapsing CDI (OR = 2.52, 95% CI = 1.11-5.72). Factors associated with 90-day mortality included higher Charlson comorbidity index score (4.34 +/- 1.71 versus 3.42 +/- 2.08, P = 0.02), severe CDI (58% versus 32%, P = 0.01), and the use of piperacillin/tazobactam (45% versus 23%, P = 0.03) or meropenem (10% versus 1%, P = 0.04). In the regression analysis, 90-day mortality was associated with severe CDI (OR = 1.76; 95% CI = 1.19-2.59). Conclusion: Fluoroquinolone use and prior stroke are associated with an increased risk of relapsing CDI. Relapsing CDI and severe CDI are both associated with increased 90-day mortality.
引用
收藏
页码:350 / 355
页数:6
相关论文
共 50 条
  • [41] Risk factors and outcomes of Clostridium difficile infection in hospitalized patients
    Lee, Hao-Yuan
    Hsiao, Hsuan-Ling
    Chia, Chin-Yuan
    Cheng, Chun-Wen
    Tsai, Tzu-Cheng
    Deng, Shin-Tarng
    Chen, Chyi-Liang
    Chiu, Cheng-Hsun
    BIOMEDICAL JOURNAL, 2019, 42 (02) : 99 - 106
  • [42] Incidence of Clostridium difficile infection in patients receiving high-risk antibiotics with or without a proton pump inhibitor
    Gordon, D.
    Young, L. R.
    Reddy, S.
    Bergman, C.
    Young, J. D.
    JOURNAL OF HOSPITAL INFECTION, 2016, 92 (02) : 173 - 177
  • [43] Risk of Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis
    Kwok, Chun Shing
    Arthur, Aaron Kobina
    Anibueze, Chukwudubem Ifeanyichukwu
    Singh, Sonal
    Cavallazzi, Rodrigo
    Loke, Yoon Kong
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (07) : 1011 - 1019
  • [44] Risk Factors for Recurrence of Clostridium Difficile-Associated Diarrhoea
    Samie, Ahmed Abdel
    Traub, Marc
    Bachmann, Klaus
    Kopischke, Karolin
    Theilmann, Lorenz
    HEPATO-GASTROENTEROLOGY, 2013, 60 (126) : 1351 - 1354
  • [45] Risk Predictors for development of Clostridium difficile infection
    Menendez, Mercedes
    Batista, Noelia
    Balsamo, Andres
    Seija, Veronica
    REVISTA MEDICA DEL URUGUAY, 2016, 32 (03): : 159 - 165
  • [46] Proton pump inhibitors and risk of Clostridium difficile infection: association or causation?
    Villafuerte-Galvez, Javier A.
    Kelly, Ciaran P.
    CURRENT OPINION IN GASTROENTEROLOGY, 2018, 34 (01) : 11 - 18
  • [47] Risk Factors for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-Analysis
    Deshpande, Abhishek
    Pasupuleti, Vinay
    Thota, Priyaleela
    Pant, Chaitanya
    Rolston, David D. K.
    Hernandez, Adrian V.
    Donskey, Curtis J.
    Fraser, Thomas G.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2015, 36 (04) : 452 - 460
  • [48] First recurrence of Clostridium difficile infection: clinical relevance, risk factors, and prognosis
    Larrainzar-Coghen, T.
    Rodriguez-Pardo, D.
    Puig-Asensio, M.
    Rodriguez, V.
    Ferrer, C.
    Bartolome, R.
    Pigrau, C.
    Fernandez-Hidalgo, N.
    Pumarola, T.
    Almirante, B.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2016, 35 (03) : 371 - 378
  • [49] The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalised patients
    Park, S. W.
    Choi, A. R.
    Lee, H. J.
    Chung, H.
    Park, J. C.
    Shin, S. K.
    Lee, S. K.
    Lee, Y. C.
    Kim, J. E.
    Lee, H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (06) : 619 - 627
  • [50] Does PPI therapy predispose to Clostridium difficile infection?
    Pant, Chaitanya
    Madonia, Phillip
    Minocha, Anil
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2009, 6 (09) : 555 - 557